Loading...

CRDL

CRDL

CARDIOL THERAPEUTICS INC

(CRDL)

2024 6-K

Investor Conference

14 May '26

Financial Report Filed

11 May '26

Publication Announcement

7 May '26

Trial Network Expansion

28 Apr '26

Filing Update

14 Apr '26

Filing Notice

10 Apr '26

Year-End Update

1 Apr '26

Conference Announcement

25 Feb '26

ARCHER Phase II Study

10 Feb '26

Underwriting Agreement

2 Feb '26

Form 6-K Filing

26 Jan '26

Financing Success

23 Jan '26

6-K Filing Report

16 Jan '26

Enrollment Milestone

13 Jan '26

New Trial Data

1 Dec '25

Filing Update

13 Nov '25

Patent Approval Achieved

13 Nov '25

Trial Results Announcement

5 Nov '25

Filing Notice

27 Oct '25

Filing Update

27 Oct '25

Financing Update

21 Oct '25

Funding Acquisition

17 Oct '25

Filing Details

14 Aug '25

Conference Participation

11 Aug '25

ARCHER Trial Results

6 Aug '25

ARCHER Trial Update

22 Jul '25

Annual Meeting Results

29 May '25

Annual Meeting Webcast

27 May '25

Financial Report

14 May '25

Board Appointment

29 Apr '25

Annual General Meeting

28 Apr '25

Clinical Trial Update

16 Apr '25

Year-End Update

1 Apr '25

Report Filing

14 Mar '25

Conference Presentation

3 Mar '25

Research Publication

20 Feb '25

Conference Presentation

4 Feb '25

Clinical Results Presented

18 Nov '24

Filing Report

14 Nov '24

Clinical Trial Update

22 Oct '24

Over-Allotment Closing

11 Oct '24

Public Offering Closed

10 Oct '24

Public Offering Announcement

9 Oct '24

Public Offering Filing

8 Oct '24

Trial Enrollment Success

24 Sep '24

Study Completion Announcement

10 Sep '24

Company Filing Update

12 Aug '24

Filing Submission

16 Jul '24

AGM Voting Results

27 Jun '24

Annual Meeting Webinar

25 Jun '24

Positive Data Announcement

13 Jun '24

Annual Meeting Notice

28 May '24

Filing Update

14 May '24

ARCHER Trial Update

14 May '24

Filing Notification

26 Apr '24

Company Update

2 Apr '24

Material Change Report

26 Feb '24

Study Enrollment Complete

21 Feb '24

Orphan Drug Designation

15 Feb '24

Listing Compliance Confirma...

24 Jan '24

Enrollment Update

9 Jan '24

External Links:

SEC

Cardiol Therapeutics Inc. reported on January 9, 2024, that it has exceeded 50% enrollment in its Phase II ARCHER Trial for Acute Myocarditis. This is a significant event for the company as it progresses in clinical trials.

AI Assistant

CARDIOL THERAPEUTICS INC

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.